<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347698</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-007</org_study_id>
    <nct_id>NCT00347698</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Intravitreal Bevacizumab Vs Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A One-Year Prospective, Contralateral Eye Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal
      bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the
      treatment of patients with untreated symmetric proliferative diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current gold standard for the treatment of proliferative diabetic retinopathy is
      panretinal photocoagulation. However, it is a treatment that results in significant
      discomfort to the patient, causes reduction of visual acuity and visual field impairment.
      Intravitreal bevacizumab is a novel treatment that reduces intraocular VEGF concentration and
      therefore inhibits neovascular proliferation, without causing significant disconfort to the
      patient, nor affecting visual acuity or visual fields (although with other risks associated
      with intravitreal injection). Making a comparison between both treatments in different
      patients is difficult because there are other variables that influence the progression of the
      disease (such as glycemic control or renal insufficiency). Therefore this study is designed
      using both treatments in the same patient: intravitreal bevacizumab in one eye, compared to
      panretinal photocoagulation in the contralateral eye, and evaluating visual acuity, visual
      fields, fluorescein angiography, optic coherence tomography of the macula, and patient
      discomfort, in a one-year follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date>August 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity at six months and one year</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular thickness measured by OCT at six months and one year</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Median deviation in visual fields at one year</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Score on a patient satisfaction scale at six months and one year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications associated to each treatment</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection of bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>panretinal photocoagulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symmetric proliferative diabetic retinopathy without high risk characteristics

          -  age 18 years or older

          -  patient consent

        Exclusion Criteria:

          -  heart attack or cerebrovascular attack

          -  only eye

          -  retinal detachment

          -  vitreous haemorrhage

          -  previous treatment for diabetic retinopathy

          -  media opacities that preclude visualization of the fundus

          -  pregnancy

          -  inability to understands the implications of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerardo García-Aguirre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerardo García-Aguirre, MD</last_name>
    <phone>+52 (55) 10841400</phone>
    <phone_ext>1172</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Reyna-Castelán, MD</last_name>
    <phone>+52 (55)10841400</phone>
    <phone_ext>1172</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México</name>
      <address>
        <city>Mexico City</city>
        <state>D. F</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoko Burgoa</last_name>
      <phone>+52 (55) 1084 1400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Mariana Martinez, MD</last_name>
      <phone>+52 (55) 1084 1400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerardo García-Aguirre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Quiroz-Mercado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Kon-Jara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitzy Torres, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Reyna-Castelan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987 Jul;94(7):761-74.</citation>
    <PMID>3658348</PMID>
  </reference>
  <reference>
    <citation>Frank RN. Visual fields and electroretinography following extensive photocoagulation. Arch Ophthalmol. 1975 Aug;93(8):591-8.</citation>
    <PMID>1171677</PMID>
  </reference>
  <reference>
    <citation>Salti H. Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Am J Ophthalmol. 2006 Feb;141(2):422; author reply 422-3.</citation>
    <PMID>16458724</PMID>
  </reference>
  <reference>
    <citation>Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003 Jan;22(1):1-29. Review.</citation>
    <PMID>12597922</PMID>
  </reference>
  <reference>
    <citation>Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 Oct 15;57(20):4593-9.</citation>
    <PMID>9377574</PMID>
  </reference>
  <reference>
    <citation>Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006 Mar;26(3):275-8.</citation>
    <PMID>16508426</PMID>
  </reference>
  <reference>
    <citation>Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006 Mar;26(3):352-4.</citation>
    <PMID>16508438</PMID>
  </reference>
  <reference>
    <citation>Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006 Mar;26(3):279-84.</citation>
    <PMID>16508427</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.</citation>
    <PMID>16156152</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):336-9.</citation>
    <PMID>16156153</PMID>
  </reference>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>June 30, 2006</last_update_submitted>
  <last_update_submitted_qc>June 30, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2006</last_update_posted>
  <keyword>diabetic retinopathy</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>photocoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

